Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...

I'm a professional photographer and I often use my iPhone on pro photoshoots. These are my top tips for getting the best results from your phone camera. When he's not testing the latest phones or ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.